Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease
Sponsor: Avanir Pharmaceuticals
Terminated
Sponsor decided to stop study early
Other terminated trials from Avanir Pharmaceuticals
A PHASE4 clinical study on Alzheimer's Disease and Pseudobulbar Affect (PBA), this trial is terminated or withdrawn. The trial is conducted by Avanir Pharmaceuticals and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE4
Status: Unknown Status → Terminated
-
Aug 2019 — Nov 2019 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Avanir Pharmaceuticals
- St. Joseph's Hospital and Medical Center, Phoenix
For direct contact, visit the study record on ClinicalTrials.gov .